Pharmacology of 5HT2C receptor-mediated ERK1/2 phosphorylation: Agonist-specific activation pathways and the impact of RNA editing

Biochemical Pharmacology

Volumn 76, Issue 10, 2008, Pages 1276-1287

  Werry, Tim D ^a   Stewart, Gregory D ^a   Crouch, Michael F ^b   Watts, Anne ^c   Sexton, Patrick M ^a   Christopoulos, Arthur ^a  

^a MONASH UNIVERSITY   (Australia)

^b TGR BioSciences   (Australia)

^c LEIDEN UNIVERSITY   (Netherlands)

Author keywords

MAP kinase; Receptor theory; RNA editing; Serotonin receptor; Stimulus trafficking

Indexed keywords

2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; ASPARAGINE; CLOZAPINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCINE; ISOLEUCINE; MATRIX METALLOPROTEINASE; MIANSERIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; QUIPAZINE; RNA; SERINE; SEROTONIN; SEROTONIN 2C AGONIST; SEROTONIN 2C RECEPTOR; VALINE;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CELL STRAIN; CELL STRAIN CV 1; CONTROLLED STUDY; DRUG MECHANISM; DRUG SPECIFICITY; ENZYME PHOSPHORYLATION; MONKEY; NONHUMAN; PRIORITY JOURNAL; RNA EDITING;

ANIMALS; CELL LINE; CERCOPITHECUS AETHIOPS; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; RECEPTOR, SEROTONIN, 5-HT2C; RNA EDITING; SEROTONIN AGONISTS;

EID: 54049141206     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.08.024     Document Type: Article

References (42)

1. Hoyer D., Hannon J.P., and Martin G.R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71 (2002) 533-554
2. Werry T.D., Loiacono R., Sexton P.M., and Christopoulos A. RNA editing of the serotonin 5HT(2C) receptor and its effects on cell signalling, pharmacology and brain function. Phamacol. Ther. 119 (2008) 7-23
3. Heisler L.K., Chu H.M., and Tecott L.H. Epilepsy and obesity in serotonin 5-HT2C receptor mutant mice. Ann NY Acad Sci 861 (1998) 74-78
4. Kenakin T. Agonist-receptor efficacy II: agonist trafficking of receptor signals. Trends Pharmacol Sci 16 (1995) 232-238
5. Urban J.D., Clarke W.P., von Zastrow M., Nichols D.E., Kobilka B., Weinstein H., et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320 (2007) 1-13
6. Berg K.A., Maayani S., Goldfarb J., Scaramellini C., Leff P., and Clarke W.P. Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 54 (1998) 94-104
7. Werry T.D., Gregory K.J., Sexton P.M., and Christopoulos A. Characterization of serotonin 5-HT receptor signaling to extracellular signal-regulated kinases 1 and 2. J Neurochem 93 (2005) 1603-1615
8. Backstrom J.R., Chang M.S., Chu H., Niswender C.M., and Sanders-Bush E. Agonist-directed signaling of serotonin 5-HT2C receptors: differences between serotonin and lysergic acid diethylamide (LSD). Neuropsychopharmacology 21 (1999) 77S-81S
9. Ahn S., Shenoy S.K., Wei H., and Lefkowitz R.J. Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. J Biol Chem 279 (2004) 35518-35525
10. Gesty-Palmer D., Chen M., Reiter E., Ahn S., Nelson C.D., Loomis C.R., et al. Distinct beta-arrestin and G protein dependent pathways for parathyroid hormone receptor stimulated ERK1/2 activation. J Biol Chem (2006) 10856-10864
11. Werry T.D., Christopoulos A., and Sexton P.M. Mechanisms of ERK1/2 regulation by seven-transmembrane-domain receptors. Curr Pharm Des 12 (2006) 1683-1702
12. Burns C.M., Chu H., Rueter S.M., Hutchinson L.K., Canton H., Sanders-Bush E., et al. Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature 387 (1997) 303-308
13. Schmauss C. Regulation of serotonin 2C receptor pre-mRNA editing by serotonin. Int Rev Neurobiol 63 (2005) 83-100
14. Berg K.A., Cropper J.D., Niswender C.M., Sanders-Bush E., Emeson R.B., and Clarke W.P. RNA-editing of the 5-HT(2C) receptor alters agonist-receptor-effector coupling specificity. Br J Pharmacol 134 (2001) 386-392
15. 2C receptor RNA editing alters receptor basal activity: implications for serotonergic signal transduction. J Neurochem 73 (1999) 1711-1717
16. Niswender C.M., Copeland S.C., Herrick-Davis K., Emeson R.B., and Sanders-Bush E. RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity. J Biol Chem 274 (1999) 9472-9478
17. McGrew L., Price R.D., Hackler E., Chang M.S., and Sanders-Bush E. RNA editing of the human serotonin 5-HT2C receptor disrupts transactivation of the small G-protein RhoA. Mol Pharmacol 65 (2004) 252-256
18. Porter R.H., Malcolm C.S., Allen N.H., Lamb H., Revell D.F., and Sheardown M.J. Agonist-induced functional desensitization of recombinant human 5-HT2 receptors expressed in CHO-K1 cells. Biochem Pharmacol 62 (2001) 431-438
19. Gurevich I., Tamir H., Arango V., Dwork A.J., Mann J.J., and Schmauss C. Altered editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims. Neuron 34 (2002) 349-356
20. Iwamoto K., and Kato T. RNA editing of serotonin 2C receptor in human postmortem brains of major mental disorders. Neurosci Lett 346 (2003) 169-172
21. Sodhi M.S., Burnet P.W., Makoff A.J., Kerwin R.W., and Harrison P.J. RNA editing of the 5-HT(2C) receptor is reduced in schizophrenia. Mol Psychiatry 6 (2001) 373-379
22. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 (1976) 248-254
23. Devlin M.G., Smith N.J., Ryan O.M., Guida E., Sexton P.M., and Christopoulos A. Regulation of serotonin 5-HT2C receptors by chronic ligand exposure. Eur J Pharmacol 498 (2004) 59-69
24. Osmond R.I., Sheehan A., Borowicz R., Barnett E., Harvey G., Turner C., et al. GPCR screening via ERK 1/2: a novel platform for screening G protein-coupled receptors. J Biomol Screen 10 (2005) 730-737
25. Motulsky H.J., and Christopoulos A. Fitting models to biological data using linear and nonlinear regression. A practical guide to curve fitting (2004), Oxford University Press, New York
26. Christopoulos A., Parsons A.M., Lew M.J., and El-Fakahany E.E. The assessment of antagonist potency under conditions of transient response kinetics. Eur J Pharmacol 382 (1999) 217-227
27. Lew M.J., and Angus J.A. Analysis of competitive agonist-antagonist interactions by nonlinear regression. Trends Pharmacol Sci 16 (1995) 328-337
28. Werry T.D., Sexton P.M., and Christopoulos A. 'Ins and outs' of seven-transmembrane receptor signalling to ERK. Trends Endocrinol Metab 16 (2005) 26-33
29. Sonee M., Barron E., Yarber F.A., and Hamm-Alvarez S.F. Taxol inhibits endosomal-lysosomal membrane trafficking at two distinct steps in CV-1 cells. Am J Physiol 275 (1998) C1630-C1639
30. Davies M.A., Setola V., Strachan R.T., Sheffler D.J., Salay E., Hufeisen S.J., et al. Pharmacologic analysis of non-synonymous coding h5-HT2A SNPs reveals alterations in atypical antipsychotic and agonist efficacies. Pharmacogenomics J 6 (2006) 42-51
31. Brady S.C., Allan L.A., and Clarke P.R. Regulation of caspase 9 through phosphorylation by protein kinase C zeta in response to hyperosmotic stress. Mol Cell Biol 25 (2005) 10543-10555
32. Wang Y., and Sul H.S. Ectodomain shedding of preadipocyte factor 1 (Pref-1) by tumor necrosis factor alpha converting enzyme (TACE) and inhibition of adipocyte differentiation. Mol Cell Biol 26 (2006) 5421-5435
33. Gerhardt C.C., Gros J., Strosberg A.D., and Issad T. Stimulation of the extracellular signal-regulated kinase 1/2 pathway by human beta-3 adrenergic receptor: new pharmacological profile and mechanism of activation. Mol Pharmacol 55 (1999) 255-262
34. Della Rocca G.J., Maudsley S., Daaka Y., Lefkowitz R.J., and Luttrell L.M. Pleiotropic coupling of G protein-coupled receptors to the mitogen- activated protein kinase cascade. Role of focal adhesions and receptor tyrosine kinases. J Biol Chem 274 (1999) 13978-13984
35. Krug A.W., Schuster C., Gassner B., Freudinger R., Mildenberger S., Troppmair J., et al. Human epidermal growth factor receptor-1 expression renders Chinese hamster ovary cells sensitive to alternative aldosterone signaling. J Biol Chem 277 (2002) 45892-45897
36. DeFea K.A., Vaughn Z.D., O'Bryan E.M., Nishijima D., Dery O., and Bunnett N.W. The proliferative and antiapoptotic effects of substance P are facilitated by formation of a beta-arrestin-dependent scaffolding complex. Proc Natl Acad Sci USA 97 (2000) 11086-11091
37. DeFea K.A., Zalevsky J., Thoma M.S., Dery O., Mullins R.D., and Bunnett N.W. Beta-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. J Cell Biol 148 (2000) 1267-1281
38. Shah B.H., and Catt K.J. GPCR-mediated transactivation of RTKs in the CNS: mechanisms and consequences. Trends Neurosci 27 (2004) 48-53
39. Boldt S., and Kolch W. Targeting MAPK signalling: Prometheus' fire or Pandora's box?. Curr Pharm Des 10 (2004) 1885-1905
40. Berg K.A., Clarke W.P., Sailstad C., Saltzman A., and Maayani S. Signal transduction differences between 5-hydroxytryptamine type 2A and type 2C receptor systems. Mol Pharmacol 46 (1994) 477-484
41. Berg K.A., Dunlop J., Sanchez T., Silva M., and Clarke W.P. A conservative, single-amino acid substitution in the second cytoplasmic domain of the human Serotonin2C receptor alters both ligand-dependent and -independent receptor signaling. J Pharmacol Exp Ther 324 (2008) 1084-1092
42. Lew M.J., Christopoulos A., and Ziogas J. Non-surmountable antagonism: transcending steady state. Trends Pharmacol Sci 22 (2001) 65-74